Kidney Cancer

Cabometyx plus Tecentriq failed to improve progression-free survival in patients with kidney cancer.

The drug duo Lenvina plus Keytruda led to improved outcomes for patients with advanced renal cell carcinoma, extended follow-up of the CLEAR trial showed.

A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.

The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, according to recent research.

Discovering different genetic mutations to target ... continues to add to the excitement.

Going through cancer is a marathon, not a sprint.

As a part of its “Speaking Out” video series, CURE® spoke with Meryl Uranga, on behalf of KidneyCAN, about the importance of working as a team with their clinicians and getting educated before making decisions.

One expert explains how the road to cancer drug development isn’t a smooth one, but progress can be made nonetheless.

FDA-approved immunotherapies offer patients with metastatic or recurrent sarcomatoid RCC more treatment choices and improved outcomes.

HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease.

Take a look at the top advancements and most popular articles about kidney cancer from the year 2022.

In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.

When Sean Korbitz was a 20-year-old college student, his life trajectory changed with a rare cancer diagnosis, resulting in the removal of 40 tumors; fifteen years later, a new drug made him feel like a “medical miracle.”

Newer drugs for kidney cancer have proven extremely effective but can cause unwanted symptoms that affect safety and quality of life.

A kidney cancer diagnosis may negatively affect a patient’s mental health; however, exercise may help put them at ease.

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga, a patient advocate, about integrative care for kidney cancer.

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga, a patient advocate, about the side effects associated with kidney cancer treatment.

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga about the importance of patients being their own advocate when communicating with their physician.

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga about the importance of patients being their own advocate when communicating with their physician.

I was misdiagnosed twice before receiving my kidney cancer diagnosis, and along the way, I learned the importance of expert doctors and clinical trials.

Once seen as a malignancy resistant to typical treatments such as chemotherapy, metastatic kidney cancer has come a long way in the past 20 years.

Twenty years of FDA approvals for the treatment of metastatic kidney cancer have allowed patients to live longer.

The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies.

Although patients treated with the combination did not have significant improvements in survival, telaglenastat and Cabometyx did not increase the rate of side effects in patients.

The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.